{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+System+Disorders&page=80",
    "query": {
      "condition": "Immune System Disorders",
      "page": 80
    },
    "page_size": 10
  },
  "pagination": {
    "page": 80,
    "page_size": 10,
    "total_count": 21025,
    "total_pages": 2103,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+System+Disorders&page=81&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+System+Disorders&page=79&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-07T11:09:06.639Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07758270",
      "title": "Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis.",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis (MS) - Relapsing-remitting"
      ],
      "interventions": [
        {
          "name": "Remibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Ocrelizumab (US)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "40 Years to 70 Years"
      },
      "enrollment_count": 15,
      "start_date": "2026-08-15",
      "completion_date": "2030-08-29",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-11-07T11:09:06.639Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07758270"
    },
    {
      "nct_id": "NCT01068873",
      "title": "Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "lopinavir/ritonavir plus maraviroc",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Temple University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2010-04",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2020-11-02",
      "last_synced_at": "2026-11-07T11:09:06.639Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01068873"
    },
    {
      "nct_id": "NCT01849783",
      "title": "Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Extramedullary Plasmacytoma",
        "Isolated Plasmacytoma of Bone",
        "Light Chain Deposition Disease",
        "Primary Systemic Amyloidosis",
        "Stage I Multiple Myeloma",
        "Stage II Multiple Myeloma",
        "Stage III Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "bortezomib",
          "type": "DRUG"
        },
        {
          "name": "thalidomide",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "autologous stem cell transplant",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Margarida Magalhaes-Silverman",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "65 Years to 85 Years"
      },
      "enrollment_count": 41,
      "start_date": "2013-04-04",
      "completion_date": "2020-09-30",
      "has_results": true,
      "last_update_posted_date": "2022-05-11",
      "last_synced_at": "2026-11-07T11:09:06.639Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01849783"
    },
    {
      "nct_id": "NCT07551583",
      "title": "Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Vinblastine",
          "type": "DRUG"
        },
        {
          "name": "Dacarbazine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": 15,
      "start_date": "2026-08-19",
      "completion_date": "2032-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-31",
      "last_synced_at": "2026-11-07T11:09:06.639Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07551583"
    },
    {
      "nct_id": "NCT01277341",
      "title": "Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic Rhinitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Seasonal Allergic Rhinitis"
      ],
      "interventions": [
        {
          "name": "Bepotastine Besilate Nasal Spray 2% Twice a day",
          "type": "DRUG"
        },
        {
          "name": "Bepotastine Besilate Nasal Spray 3% Twice a day",
          "type": "DRUG"
        },
        {
          "name": "Bepotastine Besilate Nasal Spray 4% Twice a day",
          "type": "DRUG"
        },
        {
          "name": "Placebo Nasal Spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 601,
      "start_date": "2010-12",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2020-10-05",
      "last_synced_at": "2026-11-07T11:09:06.639Z",
      "location_count": 1,
      "location_summary": "Irvine, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01277341"
    },
    {
      "nct_id": "NCT00634608",
      "title": "Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Allergic Rhinitis",
        "Asthma",
        "Back Pain",
        "Benign Prostatic Hypertrophy",
        "Bursitis",
        "Depression",
        "Anxiety",
        "Diabetes Mellitus",
        "Esophageal Reflux",
        "HIV Infections",
        "Hyperlipidemia",
        "Hypertension",
        "Insomnia",
        "Irritable Bowel Syndrome",
        "Obesity",
        "Osteoporosis (Senile)",
        "Shoulder Pain",
        "Sinusitis",
        "Symptomatic Menopause",
        "Urinary Incontinence",
        "Urinary Tract Infection",
        "Vaginitis"
      ],
      "interventions": [
        {
          "name": "Health Information Prescription",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Missouri-Columbia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 224,
      "start_date": "2008-02",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2016-09-30",
      "last_synced_at": "2026-11-07T11:09:06.639Z",
      "location_count": 1,
      "location_summary": "Columbia, Missouri",
      "locations": [
        {
          "city": "Columbia",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00634608"
    },
    {
      "nct_id": "NCT06879340",
      "title": "Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "B-Cell Non-Hodgkin Lymphoma",
        "B-cell Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "DuoCAR20.19.22-D95",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine (Conditional therapy)",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide (Conditional therapy)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2025-03-31",
      "completion_date": "2040-03",
      "has_results": false,
      "last_update_posted_date": "2026-05-14",
      "last_synced_at": "2026-11-07T11:09:06.639Z",
      "location_count": 1,
      "location_summary": "Westwood, Kansas",
      "locations": [
        {
          "city": "Westwood",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06879340"
    },
    {
      "nct_id": "NCT04282174",
      "title": "CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematologic Diseases",
        "Hematologic Malignancy",
        "Acute Lymphoblastic Leukemia",
        "Acute Myeloid Leukemia",
        "Chronic Myelogenous Leukemia",
        "Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "CliniMACS",
          "type": "DEVICE"
        },
        {
          "name": "Bone Marrow Transplant",
          "type": "PROCEDURE"
        },
        {
          "name": "Hyperfractionated Total Body Irradiation",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Baptist Health South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "Up to 74 Years"
      },
      "enrollment_count": 0,
      "start_date": "2022-09",
      "completion_date": "2030-03-01",
      "has_results": false,
      "last_update_posted_date": "2022-09-27",
      "last_synced_at": "2026-11-07T11:09:06.639Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04282174"
    },
    {
      "nct_id": "NCT01514760",
      "title": "A Pilot and Feasibility Study of Mobile-Based Asthma Action Plans",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Mobile-based Asthma Action Plan",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Arkansas Children's Hospital Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 22,
      "start_date": "2012-06",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2017-10-11",
      "last_synced_at": "2026-11-07T11:09:06.639Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01514760"
    },
    {
      "nct_id": "NCT00536120",
      "title": "The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "BG00002 (natalizumab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "keyhole limpet hemocyanin (KLH)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tetanus diphtheria toxoid vaccine (Td)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 60,
      "start_date": "2008-01",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2017-02-15",
      "last_synced_at": "2026-11-07T11:09:06.639Z",
      "location_count": 10,
      "location_summary": "Fullerton, California • Centennial, Colorado • Farmington Hills, Michigan + 7 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Farmington Hills",
          "state": "Michigan"
        },
        {
          "city": "Patchogue",
          "state": "New York"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00536120"
    }
  ]
}